Farringdon Capital’s Altimmune ALT Stock Holding History

Farringdon Capital’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-25,295	Closed	-$182K	–	340
2024 Q4	$182K	Buy	+25,295	New	+$193K	0.08%	392

Other funds holding ALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Farringdon Capital's ALT Position: Q1 2025 in Review

Farringdon Capital sold out of Altimmune (ALT) in Q1 2025, closing a stake of 25,295 shares — an estimated $182K sold.

Farringdon Capital first reported a position in ALT in Q4 2024 and held it in 1 quarter. The position peaked at $182K in Q4 2024. 176 funds tracked by Wall St. Rank hold ALT as of Q1 2025.

Farringdon Capital reported no remaining Altimmune position as of Q1 2025 after selling out during the quarter.
Farringdon Capital sold 25,295 Altimmune shares in Q1 2025, an estimated $182K.
Farringdon Capital first reported a position in Altimmune in Q4 2024 and held it in 1 quarter.
Farringdon Capital's Altimmune position peaked at $182K in Q4 2024.
176 funds tracked by Wall St. Rank held Altimmune as of Q1 2025.

Based on Farringdon Capital's 13F filing for Q1 2025, filed 15 May 2025.